NASDAQ:AEMD - Nasdaq - US00808Y4061 - Common Stock - Currency: USD
0.5834
-0.03 (-4.25%)
The current stock price of AEMD is 0.5834 USD. In the past month the price decreased by -12.27%. In the past year, price decreased by -65.68%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
SYK | STRYKER CORP | 31.4 | 145.92B | ||
MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
DXCM | DEXCOM INC | 53.81 | 34.68B | ||
RMD | RESMED INC | 26.21 | 34.03B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. The company is headquartered in San Diego, California and currently employs 14 full-time employees. The Hemopurifier, in pre-clinical studies, has demonstrated the removal of harmful exosomes from biological fluids, utilizing its lectin-based technology. The Hemopurifier is a United States Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption application related to the treatment of life-threatening viruses that are not addressed with approved therapies.
AETHLON MEDICAL INC
11555 Sorrento Valley Road, Suite 203
San Diego CALIFORNIA 92123 US
CEO: Charles J. Fisher Jr
Employees: 14
Company Website: https://www.aethlonmedical.com/
Investor Relations: http://ir.aethlonmedical.com
Phone: 16199410360
The current stock price of AEMD is 0.5834 USD. The price decreased by -4.25% in the last trading session.
The exchange symbol of AETHLON MEDICAL INC is AEMD and it is listed on the Nasdaq exchange.
AEMD stock is listed on the Nasdaq exchange.
8 analysts have analysed AEMD and the average price target is 3.95 USD. This implies a price increase of 577.49% is expected in the next year compared to the current price of 0.5834. Check the AETHLON MEDICAL INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
AETHLON MEDICAL INC (AEMD) has a market capitalization of 8.14M USD. This makes AEMD a Nano Cap stock.
AETHLON MEDICAL INC (AEMD) currently has 14 employees.
AETHLON MEDICAL INC (AEMD) has a support level at 0.4 and a resistance level at 0.63. Check the full technical report for a detailed analysis of AEMD support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
AEMD does not pay a dividend.
AETHLON MEDICAL INC (AEMD) will report earnings on 2025-06-25, after the market close.
AETHLON MEDICAL INC (AEMD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.58).
The outstanding short interest for AETHLON MEDICAL INC (AEMD) is 9.87% of its float. Check the ownership tab for more information on the AEMD short interest.
ChartMill assigns a technical rating of 3 / 10 to AEMD. When comparing the yearly performance of all stocks, AEMD is a bad performer in the overall market: 77.8% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to AEMD. AEMD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months AEMD reported a non-GAAP Earnings per Share(EPS) of -1.58. The EPS increased by 68.34% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -127.38% | ||
ROE | -187.24% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 80% to AEMD. The Buy consensus is the average rating of analysts ratings from 8 analysts.